Physician profile
Anne L Brock
NPI 1588732275
$890.35
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $774 · 2022: $101 · 2024: $14.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $181.78 | 2021 | |
| Vanda Pharmaceuticals INC. | $147.95 | 2021 | |
| Abbvie INC. | $122.29 | 2021-2022 | |
| Astellas Pharma US INC | $71.02 | 2021 | |
| Amarin Pharma, INC. | $50.84 | 2021 | |
| Dexcom, INC. | $39.26 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $38.09 | 2021 | |
| Amgen INC. | $37.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.76 | 2021 | |
| Glaxosmithkline, LLC. | $23.70 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.88 | 2021 | |
| Mylan Specialty L.P. | $18.95 | 2021 | |
| Abbott Laboratories | $16.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.38 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $14.72 | 2024 | Keveyis |
| Lilly USA, LLC | $13.85 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.32 | 2021 | |
| Alkermes, INC. | $11.93 | 2021 | |
| Eisai INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.